Administration Core

行政核心

• 批准号: 10090280
• 负责人: CLARE M TEMPANY
• 金额: $ 50.97万
• 依托单位: BRIGHAM AND WOMEN'S HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-01-06 至 2025-12-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10090280
• 关键词: Acute; Advisory Committees; Algorithms; Articulation; Attention; Beds; Biomedical Research; Cancer Biology; Clinical; Collaborations; Collection; Communication; Communities; Consultations; Data; Data Set; Development; Devices; Early Diagnosis; Ensure; Equipment; Event; Evolution; Feedback; Funding; Geographic Distribution; Geography; Goals; Grant; Group Meetings; Guidelines; Health Care Research; Heterogeneity; Human; Image; Imaging Device; Immunotherapy; Information Retrieval; Investigation; Knowledge; Leadership; Lesion; Manuscripts; Medical; Mentors; Mission; Monitor; Nanotechnology; Neoplasm Metastasis; Office of Administrative Management; Operative Surgical Procedures; Participant; Patient Care; Patients; Pattern; Phase; Policies; Procedures; Publications; Recurrence; Research; Research Activity; Research Design; Research Personnel; Resistance; Resources; Services; Strategic Planning; Technology; Testing; Time; Tissues; United States National Institutes of Health; Vision; Work; base; big-data science; biomedical resource; cancer care; cancer heterogeneity; cancer imaging; care providers; data curation; data integration; deep learning; digital; experience; image guided; image guided therapy; imaging modality; innovation; interest; meetings; neoplastic; new technology; novel; operation; overtreatment; personalized cancer therapy; personalized medicine; precision medicine; programs; research study; response; shared decision making; sound; technology research and development; tumor

The intersection of healthcare and biomedical research is at an inflection point with the convergence of cancer biology combined with new personalized therapies, the digital revolution, nanotechnology, big data science, and precision or personalized medicine. There is a wealth of meaningful information and knowledge that could be extracted from imaging data, but is currently not fully accessible by clinicians and hence cannot be optimally utilized for patient care, procedures or surgery. Medical care providers are constantly inundated with increasing amounts of patient data (both relevant and not) which are increasing in complexity. Cancer care exemplifies the current clinical challenges which include early detection, accurate distinction of pre-neoplastic and neoplastic lesions, determining infiltrative tumor margins during surgical treatment, tracking tumor evolution and potential acquired resistance to treatments over time, and prediction of tumor aggressiveness, metastasis pattern, and recurrence. Major strides have been made in the personalization of cancer therapies such as immunotherapy but the availability of specific, relevant, and timely medical data and information is of critical importance to realizing the full potential of precision medicine. Nowhere is this more acutely evident than during medical/surgical interventions in the operating and procedure rooms. Novel methods of imaging cancer to investigate the microstructure and inherent heterogeneity, image guidance, data integration, information extraction, and knowledge transfer are critical to inform and enable clinicians to fully leverage the information available, especially before, during and after invasive procedures. We are excited to propose this revised P41 biomedical resource center (BTRC) called Advanced Technologies for NCIGT or AT-NCIGT with 3 TRDs, 10 CP’s & 10 SPs. The 3 components, which we will investigate and develop new technology for are: Imaging Cancer heterogenity, Deep Learning and Intraoperative devices for image guided therapy. The BTRC will be organized with senior level experienced team led by the PI, assisted by TRD PI’s and others. They will support all research activities, ensure CP/SP support and review and mentor junior investigators and trainees. The overall goal of this proposal is to investigate, develop, and disseminate novel advanced technologies such as new MR sequences for tissue characterization-Imaging Cancer Heterogeneity (TR&D 1); analyze them and make them available through state-of-the- art algorithmic and data curation approaches (Deep Learning TR&D 2); and development of a set of comprehensive intraoperative planning, guidance and monitoring technologies and devices ( Intraoperative devices for image guided therapy TR&D 3). We will disseminate all innovations and specific deliverables to the CPs and SPs through the established mechanisms of the National Center for Image Guided Therapy (NCIGT), which continues to be dedicated to the investigation of the technical needs of IGT.

医疗保健和生物医学研究的交叉点正处于一个转折点， 癌症生物学与新的个性化疗法、数字革命、纳米技术、大数据相结合 科学，精确或个性化的医疗。有大量有意义的信息， 可以从成像数据中提取的知识，但目前临床医生无法完全访问， 因此不能最佳地用于患者护理、程序或手术。医疗服务提供者 不断被越来越多的患者数据（相关和不相关）淹没， 复杂性。癌症护理凸显了当前的临床挑战，包括早期发现， 准确区分癌前病变和肿瘤病变，确定浸润性肿瘤边缘， 手术治疗，跟踪肿瘤演变和对治疗的潜在获得性耐药性， 时间和预测肿瘤侵袭性、转移模式和复发。主要的进步有 已经在癌症治疗的个性化，如免疫治疗，但可用性， 具体、相关和及时的医疗数据和信息对于实现全面的 精准医疗的潜力这一点在医疗/手术期间最为明显 在手术室和手术室进行干预。新的成像癌症的方法，以调查 微观结构和固有的异质性，图像引导，数据集成，信息提取， 知识转移对于告知并使临床医生能够充分利用可用信息至关重要， 尤其是在侵入性手术之前、期间和之后。我们很高兴提出这一修订后的P41 生物医学资源中心（BTRC）称为NCIGT或AT-NCIGT的先进技术，具有3个TRD， 10 CP和10 SP。我们将研究和开发新技术的3个组件是： 成像癌症异质性，深度学习和术中设备的图像引导治疗。 BTRC将由PI领导的经验丰富的高级团队组织，由TRD PI协助， 他人他们将支持所有研究活动，确保CP/SP支持，并审查和指导初级 调查员和学员。本提案的总体目标是调查、开发和传播 新的先进技术，如用于组织表征的新MR序列-成像癌症 Heterogeneity（TR&D 1）;分析它们，并通过最先进的算法和 数据策展方法（深度学习TR&D 2）;以及开发一套全面的 术中计划、引导和监测技术和设备（用于 图像引导治疗TR&D 3）。我们会向各缔约方介绍所有创新成果和具体成果 和SP通过国家图像引导治疗中心的既定机制 （NCIGT），继续致力于IGT技术需求的调查。